Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance

References

• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35
   PubMed Web of Science ®Google Scholar
• Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006;12(Suppl 6):23-8
   PubMedGoogle Scholar
• Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008;14(Suppl 3):36-42
   PubMed Web of Science ®Google Scholar
• Ragni MV, Ojeifo O, Hill K, et al.J, and the Hemophilia Inhibitor Study Group. Risk factors for inhibitor formation in hemophilia: a Prevalent CaseControl Study. Haemophilia 2009;15:1074-82
   PubMed Web of Science ®Google Scholar
• Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med 1993;328:453-9
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990;323:1800-5
   PubMed Web of Science ®Google Scholar
• Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998;80:779-83
   PubMed Web of Science ®Google Scholar
• Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe hemophilia A. Haemophilia 2003;9:38-49
   PubMed Web of Science ®Google Scholar
• Musso R, Santagostino E, Faradji A, et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008;99:52-8
   PubMed Web of Science ®Google Scholar
• Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010;16:256-62
   PubMed Web of Science ®Google Scholar
• Auerswald G, Kurnik K, Blatny J, Reininger AJ. The EPIC Study: a clinical trial to assess whether early low dose prophylaxis in the absence of immunological danger signals reduces inhibitor incidence in previously untreated patients (PUPs) with hemophilia A. abstract Blood 2013;122:576
   Google Scholar
• Strauss T, Ravid B Martinowitz U, Bashari D, Kenet G. Early exposure to recombinant factor concentrates may increase inhibitor development: a single center cohort study. Haemophilia 2011;17:625-9
   PubMed Web of Science ®Google Scholar
• Kulkowska A, Komvska V, Jansen M, Lagrva P. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia 2011;17:399-406
   PubMedGoogle Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121:4046-55
   PubMed Web of Science ®Google Scholar
• Ragni MV, Bontempo FA, Lewis JH. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989;29:447-9
   PubMedGoogle Scholar
• Bray GL, Kroner BL, Arkin S, et al. Loss of high-responder inhibitors in patients with severe hemophilia A and HIV infection. Am J Hematol 1993;42:375-9
   PubMedGoogle Scholar
• Soucie JM, Symons J, Evatt B, et al. Home-based infusion therapy and hospitalization for bleeding complications among males with hemophilia. Haemophilia 2001;7:198-206
   PubMed Web of Science ®Google Scholar
• Goudemand J. Pharmacoeconomic aspects of inhibitor treatment. Eur J Haematol 1998;63(Suppl):24-7
   Google Scholar
• DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002;87:52-7
   PubMed Web of Science ®Google Scholar
• Ragni MV, Wu W, Liang X, et al. Factor VIII-pulsed tolerogenic dendritic cells reduce F.VIII inhibitor formation in the murine hemophilia A model. Exp Hematol 2009;37:744-54
   PubMed Web of Science ®Google Scholar
• Matsui H, Shibata M, Brown B, et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from FoxP3+ T regulatory cells. Blood 2009;114:677-85
   PubMed Web of Science ®Google Scholar
• Qadura M, Waters B, Burnett E, et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009;114:871-80
   PubMed Web of Science ®Google Scholar
• Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004;2:1082-95
   PubMedGoogle Scholar
• National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendation concerning prophylaxis: regular administration of clotting factor concentrate to prevent bleeding (#179). Available from: www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007
   Google Scholar
• Ragni MV, Kessler CM, Fogarty PJ, et al. Survey of current prophylaxis practice in U.S. hemophilia treatment centers. Haemophilia 2012;18:63-8
   PubMedGoogle Scholar
• Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007;109:4648-54
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Le Cessie S, van der Bom JG. Treatment characteristic and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007;5:1383-90
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013;368:231-9
   PubMed Web of Science ®Google Scholar
• Ljung R, Chambost H, Stain AM, DiMichele D. Haemophilia in the first years of life. Haemophilia 2008(Suppl 3):188-95
   PubMedGoogle Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
   PubMed Web of Science ®Google Scholar
• Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-36
   PubMed Web of Science ®Google Scholar
• Calvez T, Laurian Y. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing data are required. Br J Haematol 2006;132:798-9
   PubMedGoogle Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5
   PubMed Web of Science ®Google Scholar
• Kaczorowski DJ, Mollen KP, Edmonds R, Billiar TR. Early events in the recognition of danger signals after tissue injury. J Leukoc Biol 2008;83:546-52
   PubMed Web of Science ®Google Scholar
• EMEA. Report on expert meeting on FVIII products and inhibitors. February 28 – March 2, 2006. Available from: www.emea.europa.eu/pdfs/human/bpwg/12385/2006en.pdf [Last accessed 26 April 2010]
   Google Scholar
• Rodriguez V, Titapiwatanakun R, Moir C, et al. To circumcise or not to circumcise? Circumcision in patients with bleeding disorders. Haemophilia 2010;16:272-6
   PubMed Web of Science ®Google Scholar
• Kavakli K, Aledort LM. Circumcision and hemophilia: a perspective. Haemophilia 1998;4:1-3
   PubMed Web of Science ®Google Scholar
• Borel Y, Lewis RM, Stollar BD. Prevention of murine lupus nephritis by carrier-dependent induction of immunologic tolerance to denatured DNA. Science 1974;182:76-8
   Google Scholar
• Jiang H, Lillicrap D, Patarroyo-White S, et al. Multi-year therapeutic benefit of AAV serotypes 2, 6, 8 delivering factor VIII to hemophila A mice and dogs. Blood 2006;108:107-15
   PubMed Web of Science ®Google Scholar
• Xu L, Nichols TC, Sarkar R, et al. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA 2005;102:6080-5
   PubMed Web of Science ®Google Scholar
• Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver directed gene therapy. Blood 2002;99:2670-6
   PubMed Web of Science ®Google Scholar
• Mahlangu JN. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia 2009;15:135-41S
   PubMedGoogle Scholar
• Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013;11:132-41
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2013; doi; 10.3109/07388551.2013.834293
   PubMed Web of Science ®Google Scholar
• Borel Y. Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev 1980;50:71-104
   PubMed Web of Science ®Google Scholar
• Ephrem A, Chamat S, Miquel C Fisson S, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008;111:715-22
   PubMed Web of Science ®Google Scholar
• DeGroot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood 2008;112:3303-11
   PubMedGoogle Scholar
• Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitor by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005;105:4865-70
   PubMed Web of Science ®Google Scholar
• Liu T, Hoehn T, Hoehn S, et al. Evaluation of antibody responses to rFVIIIFc compared to Xyntha and Advate in hemophilia A mice. Haemophilia 2012;18(Suppl 3):41
   Google Scholar
• Powell JS, Josephson C, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012;119:3031-7
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell J, Ragni M, et al. Phase 3 study of long-acting recombinant factor VIIIFc in hemophilia A. Blood 2014;123:317-25
   PubMed Web of Science ®Google Scholar
• Reisner JM, Clark A, Levin L. Immunogenetics of the human immune response to factor VIII. Adv Exp Biol Med 1993;386:65-78
   Google Scholar
• Mukovozov I, Sablijc T, Hortelano G, Ofosu FA. Factors that contribute to the immunogenicity of therapeutic recombinant human proteins. Thromb Haemost 2008;99:874-82
   PubMed Web of Science ®Google Scholar
• Hu G, Guo D, Key NS, Conti-Fine BM. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007;97:788-94
   PubMedGoogle Scholar
• Singer St, Addiego JE, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996;76:17-22
   PubMedGoogle Scholar
• Lozier JN, Tayebi N, Zhang P. Mapping of genes that control the antibody response to human factor IX in mice. Blood 2005;105:1029-35
   PubMedGoogle Scholar
• Astermark J, Oldenburg J, Parlova A, et al. Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006;107:3167-72
   PubMed Web of Science ®Google Scholar
• CDC. Available from: www2a.cdc.gov/ncbddd/htcweb/Main.asp
   Google Scholar
• Hemostasis & Thrombosis Research Society. Available from: http://htrs.org
   Google Scholar
• James EA, Kwok WW, Ettinger RA, et al. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007;5:2399-407
   PubMed Web of Science ®Google Scholar
• Ettinger RA, James EA, Kwok WW, et al. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009;114:1423-8
   PubMedGoogle Scholar
• Ettinger RA, James EA, Kwok WW, et al. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia 2010;16:44-55
   PubMedGoogle Scholar
• James EA, van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost 2011;9:689-99
   PubMedGoogle Scholar
• Medical Product Safety. In healthy people 2020; 2013:222,MPS-3. Available from: www.healthypeople.gov/2020
   Google Scholar